Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss
Recurrent Pregnancy Loss Without Current Pregnancy
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss|
- The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss [ Time Frame: 3 months ] [ Designated as safety issue: No ]
|Study Start Date:||November 2012|
|Study Completion Date:||August 2013|
|Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
Patients with Abnormal Uterine Bleeding
This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus.
Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01735331
|Bagcilar Training and Research Hospital|
|Principal Investigator:||TANER A. USTA, M.D.||Bagcilar Training and Research Hospital,Istanbul,Turkey.|